Tags

Type your tag names separated by a space and hit enter

Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Int J Dermatol. 2012 Oct; 51(10):1221-5.IJ

Abstract

OBJECTIVES

Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®)) and its influence on clinical laboratory parameters.

METHODS

A total of 105 patients with suspected lesions and therapeutic features of CL diagnosed by direct smear or skin biopsy were included in this study. Intralesional injection of Glucantime(®) was administered to treat CL. Fifty-five of the 105 patients were checked for hematological features, liver and kidney function, and fasting blood sugar levels before and after treatment.

RESULTS

The observed side effects included pain (89.5%), burning sensation (81.9%), erythema (45.7%), pruritus (28.6%), secondary infection (17.1%), nausea (11.4%), vomiting (7.6%), urticaria (5.7%), necrosis (2.9%), sporotrichoid lesions (2.9%), dizziness (1.9%), dyspnea (1.9%), and anaphylactic shock (0.9%). No statistically significant differences were found in occurrences of adverse effects according to the part of the body affected, patient sex or age group, except for pruritus, which appeared more frequently in extremities than in other parts of the body (P < 0.001), and secondary infection, which was observed more frequently in people aged >45 years (P < 0.042). All clinical parameters remained normal after treatment.

CONCLUSIONS

The occurrence of severe adverse reactions, particularly of anaphylactic shock, should be considered before treatment with Glucantime(®) is initiated. Thus, it is important that intralesional Glucantime(®) injections are administered in centers that are well equipped with appropriate resuscitation and support apparatus.

Authors+Show Affiliations

Dermatology and Leishmania Research Center, Kerman University of Medical Sciences, Kerman, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22994669

Citation

Esfandiarpour, Iraj, et al. "Adverse Effects of Intralesional Meglumine Antimoniate and Its Influence On Clinical Laboratory Parameters in the Treatment of Cutaneous Leishmaniasis." International Journal of Dermatology, vol. 51, no. 10, 2012, pp. 1221-5.
Esfandiarpour I, Farajzadeh S, Rahnama Z, et al. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2012;51(10):1221-5.
Esfandiarpour, I., Farajzadeh, S., Rahnama, Z., Fathabadi, E. A., & Heshmatkhah, A. (2012). Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. International Journal of Dermatology, 51(10), 1221-5. https://doi.org/10.1111/j.1365-4632.2012.05460.x
Esfandiarpour I, et al. Adverse Effects of Intralesional Meglumine Antimoniate and Its Influence On Clinical Laboratory Parameters in the Treatment of Cutaneous Leishmaniasis. Int J Dermatol. 2012;51(10):1221-5. PubMed PMID: 22994669.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. AU - Esfandiarpour,Iraj, AU - Farajzadeh,Saeedeh, AU - Rahnama,Zahra, AU - Fathabadi,Elahe Arabpoor, AU - Heshmatkhah,Amireh, PY - 2012/9/22/entrez PY - 2012/9/22/pubmed PY - 2013/3/2/medline SP - 1221 EP - 5 JF - International journal of dermatology JO - Int J Dermatol VL - 51 IS - 10 N2 - OBJECTIVES: Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®)) and its influence on clinical laboratory parameters. METHODS: A total of 105 patients with suspected lesions and therapeutic features of CL diagnosed by direct smear or skin biopsy were included in this study. Intralesional injection of Glucantime(®) was administered to treat CL. Fifty-five of the 105 patients were checked for hematological features, liver and kidney function, and fasting blood sugar levels before and after treatment. RESULTS: The observed side effects included pain (89.5%), burning sensation (81.9%), erythema (45.7%), pruritus (28.6%), secondary infection (17.1%), nausea (11.4%), vomiting (7.6%), urticaria (5.7%), necrosis (2.9%), sporotrichoid lesions (2.9%), dizziness (1.9%), dyspnea (1.9%), and anaphylactic shock (0.9%). No statistically significant differences were found in occurrences of adverse effects according to the part of the body affected, patient sex or age group, except for pruritus, which appeared more frequently in extremities than in other parts of the body (P < 0.001), and secondary infection, which was observed more frequently in people aged >45 years (P < 0.042). All clinical parameters remained normal after treatment. CONCLUSIONS: The occurrence of severe adverse reactions, particularly of anaphylactic shock, should be considered before treatment with Glucantime(®) is initiated. Thus, it is important that intralesional Glucantime(®) injections are administered in centers that are well equipped with appropriate resuscitation and support apparatus. SN - 1365-4632 UR - https://www.unboundmedicine.com/medline/citation/22994669/Adverse_effects_of_intralesional_meglumine_antimoniate_and_its_influence_on_clinical_laboratory_parameters_in_the_treatment_of_cutaneous_leishmaniasis_ L2 - https://doi.org/10.1111/j.1365-4632.2012.05460.x DB - PRIME DP - Unbound Medicine ER -